Binovi Technologies is harnessing technology to enhance human performance
The company is using its neuro-visual performance platform to test, analyze, track and report on individual cognitive results
Sector
Health
988 stories · page 36 of 50
Ketamine One subsidiary KGK Science contracted to support a ketamine clinical trial in the US
The company said that the trial will be conducted in association with a clinic operator at its facilities in Miami, Florida
Braxia Scientific says study reveals significant reduction in depressive symptoms and suicidality with ketamine as a solo treatment
The company said ketamine has been shown to provide rapid and significant antidepressant effects in individuals with unipolar and bipolar treatment-resistant depression (TRD), and can also rapidly reduce suicidal thoughts
Universal Ibogaine is poised to address the opioid epidemic in North America with proven plant medicine
Ibogaine is a naturally occurring psychedelic substance with dissociative properties and preliminary research ndicates that it may help counter drug addiction
Genprex targets non-small cell lung cancer and diabetes via gene therapy
The US FDA has granted Fast Track Designation for REQORSA for non-small cell lung cancer in combination with AstraZeneca's Tagrisso for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso alone
Pathway Health speeds up rollout of Medical Cannabis Management System at Sobeys locations in Canada
Pathway is now reporting that it will expand the rollout to New Brunswick, Prince Edward Island, and Newfoundland, introducing the MCMS to Sobeys' Canadian pharmacy locations
Ketamine One is carving out a niche in the psychedelics industry intersecting clinical practice, research and technology
A patient walking into a Ketamine One clinic in North America can expect to be offered a range of treatments, including psychedelic-assisted options, from a skilled medical professional and guided by cutting-edge technology as part of the t
Binovi Technologies appoints Marc Lakmaaker as its new interim CEO and director
Lakmaaker has more than 20 years of executive experience, including in financial and corporate communications, corporate finance and marketing
Ketamine One signs LOI with Veteran Services USA to open therapy center
Ketamine One will leverage its experience in ketamine-assisted therapies and innovative treatments, including integrating immersive virtual reality, towards creating a first-of-its-kind healing experience specifically for veterans suffering
MagicMed Industries looking to unlock the full potential of psychedelic-derived medicines with its Psybrary
NASDAQ-listed Enveric Biosciences Inc. announced on May 24, 2021, that it has entered into a definitive agreement for an all-stock transaction to acquire the biotechnology company
Wellteq Digital Health expects FY2021 SaaS revenue to soar over 100% to top C$1.1M
The company's Software-as-a-Service (SaaS) revenue comprises about 75% of its total revenue for the year, which is projected to exceed C$1.5 million
Ketamine One partners with Psychology & Counselling Services Group to provide services to subsidiary IRP Health
PCSG, practising since 2006 and with a team of 35 health professionals, provides individual psychotherapy, couple/family therapy, psychological, as well as psycho-educational assessment and intervention for children, youth and adults
Ketamine One inks letter of intent for two ketamine infusion clinics in Texas
The company said the arrangement with Illumma LLC “bolsters the company’s proposed network of six clinics” in the US
Empower Clinics announces official opening of The Medi-Collective (TMC) inaugural medical clinic in Hamilton, Ontario
Steven McAuley, chairman and CEO of Empower Clinics said: "This is getting exciting, we are onto something special, The Medi-Collective, it's a launch!"
Pathway Health inks deal to acquire the operating assets of O Cannabis We Stand on Guard for Thee Corporation
Pathway said the acquisition adds approximately 4,000 new, active patients to the company's existing base of over 55,000 medical cannabis patients and expands its telemedicine footprint in several provinces including British Columbia and th
Little Green Pharma expands into psychedelics, receives WA Schedule 9 licence
“We have developed so much experience over the years through the cannabis industry and we genuinely believe we can now bring that to bear on the development of the psychedelics field in Australia,” says MD.
Ketamine One brings unique, computerized mental health assessment tool to North America through new agreement with Cognetivity Neurosciences
Cognetivity’s tool is a cognitive testing platform that offers a five-minute, computerized assessment that is suited to long-term mental health monitoring
Braxia Scientific reports strong revenue growth in fiscal first quarter as its sees more patients at its four clinics
The company, which is focused on treatments for depression and related conditions, said revenue for the three months came in at C$407,075
Ketamine One says subsidiary expanding with new veteran-focused clinics in Canada
The four clinics will be located in the Comox Valley, Ottawa, Halifax, and Surrey
Braxia Scientific announces Canada's first multiple-dose psilocybin clinical trial for treatment-resistant depression
The study will demonstrate that it can effectively conduct a randomized controlled trial using psychedelic-assisted therapy, enabling it to build the infrastructure for future studies and future clinical care